Enhancing chemosensitivity in pancreatic cancer: Novel strategies to overcome therapeutic resistance
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and fatal malignancies, with a 5-year survival rate of <15%. Despite significant advancements in targeted therapies and immunotherapy, these approaches benefit only a limited subset of patients, leaving chemotherapy as the primary treatment modality for most patients. Chemotherapy is an essential adjunct to surgical resection, the only potentially curative option, playing a crucial role in reducing the tumor burden, delaying disease progression, and alleviating symptoms. However, its long-term efficacy is frequently undermined by the development of chemoresistance, wherein tumor cells adopt diverse strategies to evade or repair chemotherapy-induced damage. Addressing this critical barrier is imperative for improving the clinical outcomes of PDAC. This review comprehensively examines the multifaceted mechanisms of chemoresistance in PDAC and highlights innovative strategies designed to enhance chemosensitivity, thereby offering new hope for overcoming these challenges and improving patient survival.
Authors
- Wenhao Luo (ORCID: https://orcid.org/0000-0001-9914-5338)
- Hao Chen (ORCID: https://orcid.org/0000-0002-8377-9712)
- Jinxin Tao (ORCID: https://orcid.org/0000-0001-7760-6607)
- Hua Huang (ORCID: https://orcid.org/0000-0001-6111-8019)
- Lei You (ORCID: https://orcid.org/0000-0002-1649-803X)
- Zhe Cao (ORCID: https://orcid.org/0000-0002-9379-2013)
- Bidong Fu
- Menggang Zhang (ORCID: https://orcid.org/0000-0002-4385-0158)
- Chenguang Du (ORCID: https://orcid.org/0000-0002-3548-7512)
- Yueyang Wang (ORCID: https://orcid.org/0000-0001-6475-9479)
- Liyuan Ye (ORCID: https://orcid.org/0000-0001-8592-1412)
- Guihu Weng (ORCID: https://orcid.org/0009-0008-5915-8191)
- Tao Liu (ORCID: https://orcid.org/0000-0002-5274-4445)
- Zeyu Zhang (ORCID: https://orcid.org/0000-0002-9095-2667)
- Gang Yang (ORCID: https://orcid.org/0000-0002-9654-4410)
- Chen Ding (ORCID: https://orcid.org/0000-0001-8673-3464)
- Jun Wang (ORCID: https://orcid.org/0000-0003-2509-9599)
- Shitao Jiang (ORCID: https://orcid.org/0000-0001-7298-0237)
- Taiping Zhang (ORCID: https://orcid.org/0000-0003-1689-6908)
- Yueze Liu (ORCID: https://orcid.org/0000-0001-8163-9129)
- Jiangdong Qiu (ORCID: https://orcid.org/0009-0007-9406-4863)
- Yifan Fu (ORCID: https://orcid.org/0000-0003-1678-6338)
- Yi Dong (ORCID: https://orcid.org/0009-0005-8935-364X)
- Xiaoyue Lu (ORCID: https://orcid.org/0000-0003-0761-4761)
- Jianchun Xiao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Oncology and Translational Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1097/ot9.0000000000000098
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09